Form D · Biotechnology
Qlaris Bio, Inc.
Dedham, MA · CIK 0001786717
Offering snapshot reported Jun 17, 2026 · SEC filing
- Reported sold
- $3.95M Offering amount: $3.95M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 12, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2026 | Initial | $3,946,659 | No comparison | 8 | SEC filing |
| Nov 17, 2025 | Initial | $5,641,600 | No comparison | 8 | SEC filing |
| Apr 22, 2024 | Initial | $24,032,554 | No comparison | 8 | SEC filing |
| Aug 28, 2019 | Initial | $8,164,654 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-587687
Convertible Promissory Notes
Source: Form D, filed Jun 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Danielsen | Director |
| Andrew Danielson | Director |
| Adrienne Graves | Director |
| Frederic Guerard | Director, Executive |
| Thurein Htoo | Director, Executive |
| Ron Hunt | Director |
| Ronald M. Hunt | Director |
| Wende Hutton | Director |
| Robert Warner | Director |
| Barbara Wirostko | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
770 Legacy Place 2nd Floor
Dedham, MA, 02026
Dedham, MA, 02026